ZATA is developing a nucleic acid platform technology that enables the self-delivery of oligotherapeutics that can be applied across a wide range of therapeutic areas with unmet medical needs such as cancer, infectious and genetic diseases.
ZATA is also developing a novel class of antipathogen compounds that will enable pathogen free blood products intended for transfusion.
ZATA’s emerging products will enable the enhanced of quality of health and duration of life.
ZATA team knows how to restore damaged genes (Tabatadze et.al. patent #8314226) or improve DNA and RNA molecules (Tabatadze et al (2008) NNNA. 27(2):157-72 and patent #8084589).
Cofounder of ZATA, Dr. Paul C. Zamecnik (1911-2009), co-discovered tRNA, pioneered the principles of oligotherapy that he named “antisense chemotherapy,” and discovered an essential component in the blood clotting pathway.
ZATA’s modern therapeitcs will fully satisfy all complex criteria of optimal oligotherapy compounds.
ZATA’s antipathogen compounds are capable of inactivating existing and emerging blood borne infectious agents if presented in pre-transfusion blood products.